Atomedika - Company finances
|
EUR
|
2024
From: 2024-01-03
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|
|
Financial data
|
||
| Sales revenue | 172,440 | 661,950 |
| Profit before tax | -44,784 | 34,978 |
| Net profit | -44,784 | 33,214 |
| Equity | -24,784 | 8,430 |
| Liabilities | 142,746 | 200,592 |
| Non-current assets | 743 | 387 |
| Current assets | 117,219 | 208,317 |
| Total assets | 117,962 | 208,704 |
|
Taxes paid
|
||
| STI taxes | 31,318 | 128,577 |
|
Financial indicators
|
||
| Revenue change y/y | - | +283.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -38.0% | 15.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 394.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -26.0% | 5.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -26.0% | 5.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 23.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 86,220 | 248,228 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Atomedika - Social security debts
The company had no debts to Sodra
Atomedika - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Atomedika is: 1 €
| From | To | Overdue, € |
|---|---|---|
| 2026-08-31 | 2026-09-02 | 1.18 |
| 2026-08-28 | 2026-08-30 | 1.3 |
| 2026-08-14 | 2026-08-23 | 1.3 |
| 2026-08-13 | 2026-08-13 | 9.17 |
| 2026-08-02 | 2026-08-12 | 1.3 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Atomedika, UAB (code 306653107) is a Private Limited Liability Company engaged in retail sale of other medical and orthopaedic goods. In the latest financial year, 2025, the company generated revenue of €662.0K and net profit of €33.2K, representing a profit margin of 5.0%. This was a strong improvement from 2024, when revenue was €172.4K and the company recorded a net loss of €44.8K. Revenue therefore increased sharply year on year by 283.9%, while profitability moved from loss to positive earnings. The balance sheet also expanded, with total assets rising to €208.7K from €118.0K in 2024. Equity improved from negative €24.8K to positive €8.4K, although liabilities remained higher at €200.6K. Short-term assets accounted for almost all assets at €208.3K, while long-term assets were minimal. Productivity was solid, with revenue per employee at €331.0K and profit per employee at €16.6K. Overall, 2025 shows rapid growth and a return to profitability, but the capital base remained very thin.